Drug intelligence / Profile preview

IN-C006

Development stage: Phase 3
Lead developer: HK inno.N Corporation
Administration: Intravenous

Overview

IN-C006 is an injectable pharmaceutical product developed by HK inno.N Corporation. It is currently in Phase III clinical trials to assess its safety and efficacy for providing nutritional support to postoperative patients requiring either peripheral or central parenteral nutrition.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on IN-C006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-C006.

Explore the full profile